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Abstract
Background: Biobanks provide an important foundation for genomic and personalised medicine. In order to
enhance their scientific power and scope, they are increasingly becoming part of national or international networks.
Public trust is essential in fostering public engagement, encouraging donation to, and facilitating public funding for
biobanks. Globalisation and networking of biobanking may challenge this trust.
Methods: We report the results of an Australian study examining public attitudes to the networking and
globalisation of biobanks. The study used quantitative and qualitative methods in conjunction with bioethical
analysis in order to determine factors that may contribute to, and threaten, trust.
Results: Our results indicate a generally high level of trust in biobanks and in medical research more broadly. Key
factors that can reduce perceived trustworthiness of biobanks are commercialisation and involvement in global
networking.
Conclusions: We conclude that robust ethical oversight and governance standards can both promote trust in
global biobanking and ensure that this trust is warranted.
Keywords: Biobanks, Trust, Globalisation, Commercialisation
Background
Biobanks, which can be defined as structured collections
of biological samples and associated data stored for the
purposes of present and future research [15], provide an
important foundation for genomic and personalised
medicine. Advances in computational and information
technology and data linkage platforms have greatly en-
hanced the potential of biobanks to identify biomarkers
and develop new treatments.
Typically, biobanks have been housed within, or asso-
ciated with, academic medical research institutions,
governments, or commercial organisations (such as bio-
technology or pharmaceutical companies). Increasingly,
however, biobanks are becoming part of national or
international networks, which greatly enhances their
scientific power and scope and therefore their capacity
to produce beneficial results.
A number of factors influence the sustainability of
biobanks and biobank networks. Key among these is the
degree to which potential participants trust those who
oversee biobanks to protect their interests. Empirical
and theoretical research has demonstrated the import-
ance of public trust in fostering public engagement with
biobanks, encouraging donation to biobanks, and facili-
tating public funding for biobanks [3, 5, 8, 13, 16, 17].
While there is no single definition of trust, it is gener-
ally understood as an expectation that a person will
honour an explicit or implicit commitment. Rather than
seeking a simple definition, most trust researchers oper-
ationalise trust. For example O’Neill, in assessing the
conditions in which trust is placed, considers that trust-
ing involves a belief in another person’s or institution’s
reliability, and our expectation that they are likely to
perform in a particular way – in other words, that they
will be trustworthy [14]. Trustworthiness, in turn, relates
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to the perceived competence of a person or institution
and their commitment to follow through on what they
are trusted to do. Trust, by its nature, can only be
granted by the trustor, it cannot be demanded by the
party that wishes to be trusted [10].
In the context of global biobanking, the distinction
between trust in individuals and trust in institutions is
important. A biobank donor might, for example, have
a high degree of interpersonal trust in the individual
who takes their blood sample or a doctor who requests
that they donate a tissue sample for research purposes.
While there is evidence that individuals trust their
own institutions more than they do others [6], and
that trust in the individual “agent” of a biobank is
strongly associated with that institution [4], it is not
obvious that this extends to organisations that form
networks with other organisations. An analysis of trust
in the context of biobanking networking needs,
therefore, to be cognisant of the differences between
interpersonal trust and institutional or social trust –
namely the kind of trust that we have in unknown
groups of people (such as a profession) or organisa-
tions – and needs to elucidate the factors that increase
or decrease trust in both individual biobankers and in
global biobank networks [9].
In order to make sense of the shift from interper-
sonal to institutional trust one needs to understand
the role of transitivity. Transitivity refers to the ability
of a relationship between two parties to transfer to a
third party with whom one of the others stands in a
particular relation. In terms of trust, if person A
trusts (person or institution) B, then transitivity
concerns the question of the conditions under which
A’s trust in B could extend to (person or institution)
C with which B has a relationship.
Hardin explores how we can make the shift from
individual-to-group or individual-to-institution trust,
which is a crucial transition when considering trust in
biobanks [9]. Hardin claims that in order to understand
the trust people have in government (or other institu-
tions), we need first to understand the trustworthiness
of the agents of the institution; secondly, we need to
account for the knowledge that the individual who might
engage with that institution has of its trustworthiness.
The trustworthiness of a biobank is, therefore, deter-
mined in large part by the perceived trustworthiness of
the representative of the biobank – whether a clinician,
scientist, or laboratory technician. This individual’s
trustworthiness is, in turn, grounded in their profes-
sional attributes and behaviours, as well as the creden-
tials of the institution that they represent. The process
of seeking consent from biobank donors for example,
can be an important way that the trustworthiness of the
institution is communicated to the donor.
When we consider how samples and data are shared
in the context of biobank networks – and particularly
global networks – the issue of transitivity becomes even
more important. In this context, ongoing trust depends
on the degree to which a person’s trust in the biobank
to which they donated “travels” with their sample and/or
data if it is shared with other biobanks. In addition to
individual-to-institution transitivity, networking also
makes salient the transitivity of trust between
institutions.
A previous study of Australian biobank donors found
that study participants were willing to cede some privacy
and control over their sample and/or data, as long as
they trusted the collecting biobank [3]. Research from
the United States (U.S.) suggests that trust in biomedical
research is associated with lower levels of privacy con-
cerns, and that higher levels of trust are inversely related
to preferences for notification about future use of speci-
mens [20]. U.S. research also suggests that people are
more likely to support sharing their genomic data with
U.S. researchers, and that support for data sharing
diminishes in relation to non-U.S. researchers [11].
Extending this work, we have conducted an empirical
study into the ethics and politics of global biobank
networks, exploring attitudes towards global biobank
networking.
Here we present results from two empirical phases of
the project: a national survey and in-depth interviews.
We focus on the results related to willingness to donate
to a biobank, and preferences about allowing broad
consent for future use of samples. We take both of
these to be indicators of trust, based on both a
conceptual rationale (stemming from definitions of
trustworthiness) and previous empirical research dem-
onstrating that willingness to donate, consent, and trust
are connected [3, 20]. There are also other possible
explanations for willingness to donate and to allow a
broad, open-ended consent, such as familiarity and
altruism, that might not be reducible to trust. However,
it seems likely that trust is a major explanatory concept.
Willingness to donate was assessed in the survey, and
attitudes towards trust were explored in greater depth
in interviews, both with participants who were generally
willing to donate, and also those who were generally
opposed to donating samples to biobanks. To assess
transitivity of attitudes that indicate trust, we assessed
the extent to which they shift when moving from the
Australian to a global context.
Method
This study was conducted in Australia between 2017
and 2018. The measures and sample were part of a
larger study designed to assess a wide range of issues
associated with the globalisation of biobanks. Here we
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present the results of two phases of the project: a com-
puter assisted telephone interview (CATI) survey and
follow-up semi-structured interviews with members of
the Australian public. Ethics approval for the CATI
survey and interviews were granted by Swinburne Uni-
versity and The University of Sydney ethics committees
respectively.
Biobank survey
A total of 750 Australians over the age of 18 years who
could speak English participated in the CATI survey
which ran for 3 weeks in November 2017. Telephone
numbers (61.3% mobile, 38.7% landline) were randomly
generated by Samplworx, and were designed to represent
the proportion of residents residing in each Australian
State and Territory. The margin of error was 3.5% at the
95% confidence interval where responses are assumed to
be evenly split (i.e., 50%), and response rates according
to the American Association for Public Opinion Re-
search (AAPOR)‘s (2009) definitions and calculations
(i.e., RR1 – RR4) ranged from 6.0–9.0% with a cooper-
ation rate of between 13.8–15.4%. The sample was
representative of the Australian population in relation to
state and territory, gender (52.4% women) and employ-
ment status, but was overrepresented by older people
(M = 50.85, SD = 18.01, Range = 18–91) and those with a
university education (48.3%). 82.1% described their
ethnicity as Australian.
The survey consisted of 48 forced choice questions,
meaning that participants were required to choose an
option out of the available responses for each question.
The questions were designed to explore issues relating
to participation in and support for Australian and inter-
national biobanks including: overall willingness to
donate/participate, identifiability of samples, ethics, con-
sent preferences, participant engagement, withdrawal,
funding, payment for participation, perceived benefits
and governance. The survey is provided in Additional
file 1; here we outline the questions of greatest relevance
to trust.
Prior to completing the CATI survey, all survey
respondents were read a definition of biobanks.1 This
was important given that only 26.4% indicated that they
“know enough about medical research involving
biobanks?” (71.3% answered ‘No’ and 2.3% ‘Unsure’).
Willingness to donate/participate: immediately after
the definition was read, survey respondents were asked
whether they would be willing to participate in four
biobanks with varying levels of globalisation:.
1. A biobank that was located entirely within Australia
and used only by Australian researchers
2. An Australian biobank that allows its samples to be
used by researchers located overseas
3. An Australian biobank that sent some of its samples
to be stored in a biobank overseas
4. A biobank located overseas (i.e. a bank that is
located entirely overseas and used by researchers
located overseas)
To avoid order effects, the order of the four responses
was randomly presented throughout the survey.
Willingness to store tissue according to identifiability:
six questions were designed to assess respondents’ will-
ingness to allow samples stored at three different levels
of identifiability (coded, anonymous and identifiable) to
be stored and used by either Australian or foreign
biobanks. The three different sample categories were
defined to all participants as follows (and in order of
presentation):
Coded
‘Biological samples (like DNA, blood, cancer speci-
mens and so forth) are usually given a code so that
researchers do not know who you are, but can link
back to other information about you for research
purposes. While protections are put in place, a small
risk of loss of confidentiality still remains.’
Anonymous
‘Biobanks can also store samples anonymously.
Anonymous samples are samples that have been de-
identified so that no one is able to work out who
had donated the sample.’
Identifiable
‘Sometimes biological samples can be completely
identifiable (i.e. the researchers and anyone else
who accesses the sample would know who you are).’
After each definition, respondents were asked two
questions, “Would you be willing to have a coded/an-
onymous/identifiable sample stored and used by an
Australian biobank” and “Would you be willing to have
a coded/anonymous/identifiable sample used and stored
by biobank researchers located overseas”. The response
1The script for the definition of biobanks was: “I’d like to begin by
giving you a little information about biobanks. Biobanks are collections
of biological samples, such as DNA, blood, cancer specimens, etc. that
are stored for multiple purposes. In some cases, people are asked to
donate their samples for medical research. Biobanks once used to be
localised in one place. Today, however, biobanks are going global,
which means that tissue collected in one location may be stored and/
or used by researchers all over the world.”
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options were ‘Yes’, ‘No’ or ‘Unsure’, and the order of the
two questions was randomly presented.
The questions were designed to determine how the
variation of factors such as biobank location and
identifiability of samples affected willingness to donate.
The impact of commercialisation of biobanks was also
assessed (see Additional file 1).
Consent preferences: participants were asked six
questions about their preferences for consent under
different conditions, Two questions related to oversight
by Human Research Ethics Committees, and the other
four questions asked participants for their consent pref-
erences in different scenarios (see Additional file 1)).
The kinds of permission or consent were defined for all
participants as follows, including the option of refusal of
consent:
None
‘I would not give consent for my sample to be used
for any research study.’
Specific consent
‘I would like to be asked permission before each
new study that uses my tissue.’
Conditional consent
‘I would want to give consent on the basis that it
was used for certain studies and not others.’
Broad consent
‘I would want to give consent so that my sample
could be used for any project.’
Survey respondents were asked what kind of consent
they preferred, depending on whether they were donat-
ing tissue to an Australian biobank used only by Austra-
lian researchers, an Australian biobank that allows its
samples to be used by overseas researchers (with sam-
ples stored either in Australia or overseas), and if they
were donating to a foreign biobank. They were also
asked about their consent preferences depending on
whether or not future proposed research using their
sample would be approved by a Human Research Ethics
Committee.
Qualitative interviews
In order to gain a more comprehensive and nuanced
understanding of the attitudes and beliefs that moti-
vated participants’ responses to the survey, semi-
structured interviews were conducted with 16
participants recruited from the survey. These 16 par-
ticipants were drawn from a random subset of the
CATI survey categorised into four groups according
to their age and willingness to donate to an inter-
national biobank: Younger supporters (YS), Older
supporters (OS), Younger opposers (YO) and Older
opposers (OO). Participants were identified as either
“supporters” or “opposers” based on their responses
to four key questions about their willingness to
donate to a biobank and for their sample to be used
in biobank research under various conditions. More
detail about the criteria for assigning respondents into
these groups is in Additional file 1. Four people were
interviewed from each sub-group.
An interview schedule was developed in consult-
ation with expert members of the research team,
drawing upon topics covered in the CATI survey—in-
cluding participants’ willingness to donate to local
and international biobanks, attitudes towards the
storage and sharing of samples and data, as well as
preferences for different kinds of permission or
consent. In addition to the four types of consent
described in the survey, qualitative interviews intro-
duced the concept of dynamic consent, which uses a
technology platform to allow donors to change their
consent preferences over time.
Two members of the research team (MW and LD)
were responsible for recruiting participants drawn from
a random sample of survey respondents across different
categories, and conducting the interviews. Interviews
took place between May and July 2018, approximately 8
months after the CATI survey, and lasted between 20
and 45min. All interviews took place via telephone, and
verbal or written consent was obtained from all partici-
pants prior to the interview. All interviews were digitally
recorded and transcribed.
Transcripts were entered into NVIVO 11 and were
coded by MW and LD. The coding procedure was in-
formed by Morse’s outline of the cognitive basis of quali-
tative research, [12] and Charmaz’s outline of data
analysis in grounded theory [1]. This process involved
initial line-by-line coding and gerunding to encode
process and action. The codes were then synthesised
into categories, and subsequently abstracted into con-
cepts. A process of constant comparison was applied
throughout the data analysis, with codes, categories and
concepts refined and reorganised, as new codes, categor-
ies and concepts emerged.
Results
Willingness to donate
Close to 94% of survey respondents indicated they would
be willing to donate a sample to an Australian biobank
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(see Table 1), with interviews similarly reflecting a highly
positive attitude towards medical research:
“I’m very much in favour of all types of scientific
research … that’s the most important thing.” [OS].
Two significant variables found in the survey to influ-
ence willingness to donate to, biobanks were: 1) the
location of the biobank (within Australia as opposed to
overseas), and 2) whether the research was being
conducted by a commercial entity as opposed to a not-
for-profit institution.
While 94% of survey respondents would consider do-
nating tissue to a biobank located in Australia and used
only by Australian researchers, only 63% of respondents
would consider donating tissue to a biobank located
overseas, with 33% saying they would not consider
donating to an overseas biobank (see Table 1).
Survey respondents were also significantly more
willing to donate to a biobank that was government
funded (86%) or part of a public research institution
(94%), as compared to one funded by or associated with
a pharmaceutical company (57%) or a biotechnology
firm (59%).
Interviews similarly revealed concerns about profit-
motivated research whether conducted in Australia or
abroad:
“I wouldn’t want an item to be donated for the
purpose of … benefit from a commercial point of
view.” [YO].
“I’d probably be more inclined or trusting some-
thing like a university or a not-for-profit.” [YO].
“I dislike the idea of other countries mooching off
us and then making a profit.” [OO].
However, for many participants the concerns about
commercialisation were less persuasive than a desire to
support medical research:
“I’d probably be okay with both as long as the
purpose is kind of still good.” [YO].
“I do have a preference for the not-for-profit using
the tissues, but if it gets to the point where a
commercial medical research company needs or
Table 1 Frequency And Percentage Of Responses For Willingness To Donate And Identification Of Samples
Question Yes No Unsure
Willingness to donate
A biobank that was located entirely within Australia and used only by Australian researchers 706 31 13
94.1% 4.1% 1.7%
An Australian biobank that allows its samples to be used by researchers located overseas 619 107 24
82.5% 14.3% 3.2%
An Australian biobank that sent some of its samples to be stored in a biobank overseas 606 123 21
80.8% 16.4% 2.8%
A biobank located overseas (i.e. a bank that is located entirely overseas and used by researchers located overseas) 469 244 37
62.5% 32.5% 4.9%
Identification of samples
Coded samples - Stored and used by an Australian biobank 656 72 22
87.5% 9.6% 2.9%
Coded samples - Used or stored by biobank researchers located overseas 448 266 36
59.7% 35.5% 4.8%
Anonymous Samples - Stored and used by an Australian biobank 706 34 10
94.1% 4.5% 1.3%
Anonymous Samples - Used or stored by biobank researchers located overseas 570 161 19
76.0% 21.5% 2.5%
Identifiable Sample - Stored and used by an Australian biobank 494 217 39
65.9% 28.9% 5.2%
Identifiable Sample - Used or stored by biobank researchers located overseas 314 401 35
41.9% 53.5% 4.7%
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uses tissues for research and their research benefits
me and let’s say people who have my health condi-
tion, then that’s okay as well.” [YS].
Governance and ethical standards for research were
also factors that had a significant influence on willing-
ness to donate. There was a preference among 76% of
participants that samples donated to an overseas
biobank would be handled, stored and used according to
Australian ethical standards and governance procedures.
Willingness to donate to an overseas biobank was higher
if the biobank operated under the standards of a multi-
national organisation (66%) as compared to the stan-
dards of a foreign government (35%). This suggests that
participants view the ethical standards developed by a
number of countries working together as more trust-
worthy than a single foreign government, although
Australian standards were perceived as the most
trustworthy.
Control over samples and data
Survey respondents tended to be permissive when it
came to types of consent to both Australian and global
biobanks, with broad consent being the most preferred
form of consent. Many interview respondents did not
express strong preferences to retain control over their
samples, with participants commenting that: “I’d be
happy with a broad blanket consent for any kind of
future research” [YS], and “you can use my DNA for
anything really” [YS]. Qualitative interviews that
discussed dynamic consent did not have a significant
impact on consent preferences.
Appropriate ethical oversight of future research involv-
ing their sample and/or data was an important concern
for many respondents and a prerequisite for broader
forms of consent. A clear majority (85%) of survey
participants wanted future research projects using their
tissue sample to be approved by an ethics committee
regardless of whether the biobank was located in
Australia or overseas.2 Interviews similarly pointed to
the need for appropriate ethical oversight—particularly
when consent is open-ended and where tissue was
shared with overseas biobanks.
“I would like to know that it was a fairly rigorous
protocol that was in place.” [OS].
“I would need to know that all the protocols were
absolutely spot [on] if you like, before I would like it
to go to another country.” [OS].
“If it’s going to an approved biobank … it’s going to
be done properly.” [YO].
However, respondents were less willing to support
broad consent to the use of tissue or data by an
overseas (36%) compared to Australian (53%) biobanks
(see Table 2 for further details of consent preferences),
and some interview participants expressed reluctance
about losing control over their samples or data if they
were sent overseas:
“I wouldn’t want to just let it go and not have any
control over what happens to it.” [YO].
Identifiability of samples
The survey revealed that identifiability of samples influ-
enced how willing people were to have their sample
and/or data stored by an Australian or overseas biobank.
If samples were identifiable, 66% of respondents would
agree to donate a biological sample for storage and use
by an Australian biobank. However, only 42% would
donate an identifiable sample for storage or use by a
biobank located overseas. Qualitative interviews also
suggested that some participants would be uncomfort-
able with their identifiable data being shared with other
biobanks:
“… just the privacy thing …” [YS].
“… want it anonymous …” [YS].
There was a similar disparity for anonymous3 samples,
with almost all respondents (94%) being willing to have
an anonymous sample used and stored by an Australian
biobank, compared to 76% being willing to provide an
anonymous sample for use or storage overseas. For de-
identified samples, 60% of respondents would allow a
coded sample to be used or stored overseas, compared
to 88% being willing to have a coded sample stored and
used by an Australian biobank.
2Our data showed that 92% of respondents would want ethics approval
for future research conducted by an Australian biobank, and 88% want
ethics approval for research conducted by an overseas biobank.
Following analysis of the small group (n = 43) who wanted ethics
approval for Australian but not for foreign biobank research we
suspect this disparity is due to error and/or misunderstanding, since
respondents in this group were significantly less likely to be willing to
donate to overseas biobanks, including those operating under the
standards of a foreign government.
3Survey respondents were asked about having their sample stored
anonymously. However, we acknowledge that in the genomic age it is
now questionable whether true anonymisation is possible. See, for
example Erlich, Shor, Pe’er, & Carmi [7].
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Particularly when it came to overseas biobanks, many
people preferred their sample to be fully anonymised3:
“… don’t really want my name put on these sort of
things …” [YS].
“I just want to give my sample and be done with it.”
[YS].
Discussion
This study is consistent with most other research in this
area in that we found high levels of support for research
and trust in the enterprise of biobank-based research [2,
18], and also higher levels of trust in public compared to
private biobanks [3]. We found that the predominant
aspects of biobank practice that influence public trust
are lack of commercial involvement (supporting earlier
findings), and location within Australia. This was evident
in a higher willingness to donate; a preference for more
open-ended consent (where the researcher or institution
is entrusted to use the material in ways that are accept-
able to the donor); and less concern about potential re-
identification (which suggests the belief that personal
information will be safeguarded and used appropriately).
Furthermore, we found that ethical oversight of future
research is important for ensuring the transitivity of
trust.
Since trust is essential to the enterprise of biobank-
based research, the lower levels of trust that the public
appears to have in global biobank networks and in
commercialisation of biobanking present important
challenges to the expansion and globalisation of
biobank-based research. In this regard, those involved in
biobanking need to be alert to both the fragility of trust
[19], and the fact that trust is something that cannot be
demanded, but must be earned and conferred willingly
by the trustor [10]. The fact that ethical oversight and
standards of governance had a strong influence on
participants’ willingness to donate—whether to local or
international biobanks—suggests that, with the right
kind of governance, it may well be possible to maintain
and enhance trust. Visibility of ethical oversight and
clear communication of governance standards becomes
an important way that biobanks can demonstrate their
trustworthiness to potential donors, and to maximise the
potential for transitivity of that trustworthiness.
In this regard, it is particularly important for bio-
banks engaging in global networking to consider how
their networking arrangements might influence the
transitivity of trust. We observed a clear preference
for Australian ethical standards and governance
procedures to be applied even to international
biobanks, as well as a belief that several countries
working together to develop harmonised standards for
ethical governance is preferable to any individual for-
eign country’s standards. Governance arrangements
that explicitly ensure that Australian ethical standards
are upheld by all researchers who might have access
to samples or data via the global network may also
be an important way that individual biobanks can
demonstrate their trustworthiness.
A potential limitation of our study is we did not meas-
ure trust directly, but rather made an inference from
measures of willingness to donate to a biobank under
different conditions. While strong connections between
trust and willingness have been established [3, 20], they
are conceptually distinct. Trust was however explicitly
explored in the qualitative interviews, and this confirmed
its close relationship to willingness to donate, to provide
broad consent and to generally positive attitudes towards
global biobanks. Another limitation is that participants
were on average older and more highly educated (with a
greater proportion of university educated people) when
compared to the general population. As such, the views
and attitudes expressed in this study may not generalise
to the wider Australian public. Both quantitative and
qualitative phases were potentially affected by social
desirability bias, although efforts to address this were
made in the interviews, by stratifying participants into
supporters and opposers.
Table 2 Frequency And Percentage Of Responses For Consent Options







An Australian biobank that is used only by Australian researchers 28 141 185 392 4
3.7% 18.8% 24.7% 52.3% 0.5%
An Australian biobank that allows its samples to be used by overseas researchers 87 168 190 301 4
11.6% 22.4% 25.3% 40.1% 0.5%
An Australian biobank that stored its samples overseas and allowed these samples to be used
by researchers located overseas
95 167 191 289 8
12.7% 22.3% 25.5% 38.5% 1.1%
A foreign or overseas biobank 131 173 165 267 14
17.5% 23.1% 22.0% 35.6% 1.9%
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Given that appropriate ethical oversight of future re-
search using participants’ sample and/or data is an im-
portant factor in determining whether trust will be
sustained, careful attention needs to be paid not only to
overall models of governance but also to specific pro-
cesses, such as consent. This is because the consent
process is not only about obtaining permission to take a
sample, but also allows the donor to express their values
and preferences with respect to how their sample will be
used, albeit to varying degrees depending on whether
consent sought is broad or specific. Trustworthiness can
be therefore be demonstrated by communicating to do-
nors explicitly that – even in the context of global net-
working or the involvement of commercial entities –
their sample and data will be used in ways that align
with their preferences and values regarding research and
the use of their tissue.
Clear material transfer agreements and other proced-
ural mechanisms that operationalise biobank networking
might also go some way towards addressing concerns
about globalisation and commercialisation, if they are
communicated in an accessible way to the public. Such
agreements can help to make it transparent that bio-
banks are cognisant of the risks of globalisation and
commercialisation and that research will be conducted
with a high level of ethical oversight. Developing such
mechanisms and communicating them in an appropriate
way with a view to fostering the transitivity of trust can
help to build public trust in the practice of global bio-
bank networking.
Conclusion
Globalisation has transformed many aspects of biomed-
ical research, including research using collections of tis-
sue and data. While globalisation of biobanking has
enormous scientific potential there are several practical
measures that need to be taken by those seeking to con-
tribute to or build biobank networks in order foster pub-
lic trust and its transitivity. Rigorous ethical oversight
that incorporates recognisable standards, robust systems
for stakeholder engagement, meaningful consent pro-
cesses, strategic and authentic communication, and at-
tention to the just distribution of research benefits will
both promote trust in global biobanking and ensure that
this trust is warranted.
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